SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10. Juli 2024 09:00 ET
|
SeaStar Medical Holding Corporation
DENVER, July 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), today announced it has entered into a definitive agreement for the issuance and sale of...
SeaStar Medical Announces 25-for-1 Reverse Stock Split
06. Juni 2024 08:30 ET
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time
22. August 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury
19. April 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, April 19, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Holding Corporation Closes Initial $3.3 Million Tranche of $9.8 Million Private Placement
16. März 2023 08:00 ET
|
SeaStar Medical Holding Corporation
DENVER, March 16, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical (NASDAQ: ICU) Commences Trading on Nasdaq Capital Market and Outlines Corporate Strategy and Near-Term Catalysts
31. Oktober 2022 09:25 ET
|
SeaStar Medical Holding Corporation
– Company advancing clinically proven platform therapy, the Selective Cytopheretic Device (SCD), to address the life-threatening consequences of hyperinflammation – SCD lead program in Acute...